Centessa announces pricing of Initial Public Offering
Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today the pricing of its initial public offering of 16,500,000 American Depositary Shares (“ADSs”), each representing one ordinary share at a public offering price of $20.00 per ADS. All of the ADSs are being offered by Centessa. The gross proceeds to Centessa from the offering, before deducting underwriting discounts, commissions and other estimated offering expenses, are expected to be approximately $330.0 million. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,475,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “CNTA” on May 28, 2021. The offering is expected to close on June 2, 2021, subject to the satisfaction of customary closing conditions.
Morgan Stanley, Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 27, 2021. The offering is being made only by means of a written prospectus. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at firstname.lastname@example.org; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10012, by telephone at 877-821-7388 or by email at prospectus_department@Jefferies.com; and Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474 0200, or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.